KLOW vs GLOW: How the Two Research Blends Differ

KLOW and GLOW are lyophilized research blends that share the same three core peptides in the same amounts: 10 mg BPC-157, 10 mg TB-500 (thymosin beta-4) and 50 mg GHK-Cu. The only difference is that KLOW adds 10 mg of KPV, an α-MSH-derived tripeptide studied in epithelial cell signaling models. That brings KLOW to 80 mg per vial against GLOW's 70 mg.

Side-by-side composition

Because the BPC-157, TB-500 and GHK-Cu masses are identical, the three shared components end up at the same concentration in either blend when both are brought to the same working volume. KPV is the only variable. For labs that want to look at KPV's contribution, the pair works as a matched comparison: GLOW serves as the KPV-free control for KLOW.

The shared core: BPC-157, TB-500 and GHK-Cu

BPC-157

A 15-residue synthetic peptide (1419.53 Da, CAS 137525-51-0) whose sequence is gastric in origin [1]. It is not an approved drug. In isolated rat aorta it produced nitric-oxide-mediated vasodilation, and in endothelial cells it activated a Src–Caveolin-1–eNOS pathway [2]. Its broader vascular literature, including VEGF signaling, has been reviewed [3]. More in the BPC-157 research overview.

TB-500 (thymosin beta-4)

Full-length thymosin β-4 is a 43-residue, N-terminally acetylated peptide (4963.44 Da, CAS 77591-33-4). It forms a 1:1 complex with monomeric actin and inhibits its polymerization [4]. It has been studied in models of coronary vessel development and epicardial progenitor differentiation [5], and its reported activities include ILK/PINCH/Akt signaling [6]. More in TB-500 and thymosin beta-4.

GHK-Cu

The copper(II) complex of the tripeptide Gly-His-Lys (about 402.9 Da as the complex, CAS 89030-95-5). In fibroblast cultures it has been examined for effects on collagen synthesis [7] and sulfated glycosaminoglycan synthesis [8]. It accounts for most of each vial's mass and gives both blends their blue color. More in GHK-Cu: the copper tripeptide in research.

The difference: KPV

KPV is the tripeptide Lys-Pro-Val (342.43 Da, C₁₆H₃₀N₄O₄, CAS 67727-97-3), the C-terminal residues 11–13 of α-melanocyte-stimulating hormone (α-MSH). Its research profile sits in a different area from the other three components:

• Structure. α-MSH is a linear 13-residue peptide, and KPV is its C-terminal sequence. A molecular dynamics study mapped the conformational space of the capped tripeptide Ac-Lys-Pro-Val-NH₂ and used the lowest-energy conformations as templates for designing constrained analogues [9].
• Airway epithelium. In immortalized human bronchial epithelial cells, KPV inhibited NF-κB signaling, and the author linked this to interference with p65RelA nuclear import [10].
• Keratinocyte signaling. In human keratinocytes, KPV did not raise cyclic AMP. It did trigger rapid intracellular calcium signals, as it also did in cells engineered to express the melanocortin-1 receptor [11].
• Receptor question. The same study notes that it was not known whether KPV acts through the melanocortin-1 receptor or cyclic AMP. Its receptor mechanism remains unresolved [11].

In short, GLOW's components are mostly studied in angiogenesis, actin dynamics, cell migration and extracellular matrix models. KLOW adds a peptide studied mainly in epithelial cell signaling models, including NF-κB pathway work.

Which blend fits a study design

Both blends are also available as Made in USA lots: KLOW, Made in USA and GLOW, Made in USA.

Analytical differences on the COA

Adding a fourth component changes what the certificate of analysis should show. A GLOW chromatogram should resolve three main peaks and a KLOW chromatogram four, each at its own retention time. KPV, like GHK, is a small, polar tripeptide. A published stability-indicating reverse-phase HPLC method for KPV identified lysyl-proline diketopiperazine as its main degradation product under acid, alkali and peroxide stress [12]. Pay attention to how well the early-eluting region is resolved. Check that the mass spectrometry section confirms every listed component and that the purity figure states whether it's per component or combined. See how to read a certificate of analysis and HPLC purity explained, and look up batch documents in the COA registry.

Storage and handling

Both blends are handled the same way. Store lyophilized vials at −20 °C, away from light and moisture. After reconstitution, keep the solution at 2–8 °C and avoid repeated freeze–thaw cycles. For a blend, plan around the stability of its least stable member.

Common questions

Is KLOW just GLOW with KPV added?

By composition, yes. The two vials hold identical amounts of BPC-157, TB-500 and GHK-Cu, and KLOW adds 10 mg of KPV. Nothing else differs in the stated formulation.

Can KPV be sourced on its own?

Yes. Single-compound KPV lets a lab add the tripeptide to a GLOW-based design at a concentration it controls, instead of using the fixed ratio in KLOW.

For a full profile of the four-component blend, see the KLOW peptide blend overview.

References

1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014. PubMed
2. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020. PubMed
3. Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014. PubMed
4. Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991. PubMed
5. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007. PubMed
6. Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010. PubMed
7. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PubMed
8. Wegrowski Y, et al. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992. PubMed
9. Chavatte P, et al. Conformational analysis of tripeptide Ac-Lys-Pro-Val-NH2, COOH-terminal sequence of alpha-MSH. J Pharm Pharmacol. 2001. PubMed
10. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012. PubMed
11. Elliott RJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004. PubMed
12. Pawar KR, et al. Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr. 2015. PubMed